Alkermes plc
US ˙ NasdaqGS ˙ IE00B56GVS15

Introduction

This page provides a comprehensive analysis of the known insider trading history of Corp Plc Elan. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Corp Plc Elan has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:PRTA / Prothena Corporation plc 10% Owner 0
US:LPCN / Lipocine Inc. 10% Owner 800,394
US:ALKS / Alkermes plc 10% Owner 7,750,000
US:ARMP / Armata Pharmaceuticals, Inc. 10% Owner 11,626,282
US:DOR / Dynamic Offshore Resources, Inc. 10% Owner 162,600
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Corp Plc Elan. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases ALKS / Alkermes plc - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ALKS / Alkermes plc. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ALKS / Alkermes plc Insider Trades
Insider Sales ALKS / Alkermes plc - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ALKS / Alkermes plc. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2012-03-13 ALKS ELAN CORP PLC 24,150,000 15.8000 24,150,000 15.8000 381,570,000 80 15.12 -16,422,000 -4.30

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ALKS / Alkermes plc Insider Trades
Insider Purchases ARMP / Armata Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ALKS / Alkermes plc. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2000-08-09 TGEN ELAN CORP PLC 382,739 13.0640 15,516 322.2453 5,000,102 730

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ARMP / Armata Pharmaceuticals, Inc. Insider Trades
Insider Sales ARMP / Armata Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ALKS / Alkermes plc. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2005-01-06 TGEN ELAN CORP PLC 43,600 1.7500 1,768 43.1667 76,300 730 5.41 -66,741 -87.47
2005-01-05 TGEN ELAN CORP PLC 10,200 1.8000 414 44.4000 18,360
2005-01-05 TGEN ELAN CORP PLC 14,465 1.7600 586 43.4133 25,458
2005-01-05 TGEN ELAN CORP PLC 225,335 1.7500 9,135 43.1667 394,336
2005-01-04 TGEN ELAN CORP PLC 950 1.8100 39 44.6467 1,720
2005-01-04 TGEN ELAN CORP PLC 1,400 1.8000 57 44.4000 2,520
2005-01-04 TGEN ELAN CORP PLC 6,400 1.7800 259 43.9067 11,392
2005-01-04 TGEN ELAN CORP PLC 20,690 1.7700 839 43.6600 36,621
2005-01-04 TGEN ELAN CORP PLC 3,800 1.7600 154 43.4133 6,688
2005-01-04 TGEN ELAN CORP PLC 24,500 1.7500 993 43.1667 42,875
2005-01-04 TGEN ELAN CORP PLC 7,591 1.7200 308 42.4267 13,057
2005-01-04 TGEN ELAN CORP PLC 1,750 1.7100 71 42.1800 2,992
2005-01-04 TGEN ELAN CORP PLC 77,919 1.7000 3,159 41.9333 132,462

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ARMP / Armata Pharmaceuticals, Inc. Insider Trades
Insider Purchases LPCN / Lipocine Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ALKS / Alkermes plc. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

LPCN / Lipocine Inc. Insider Trades
Insider Sales LPCN / Lipocine Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ALKS / Alkermes plc. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

LPCN / Lipocine Inc. Insider Trades
Insider Purchases PRTA / Prothena Corporation plc - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ALKS / Alkermes plc. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

PRTA / Prothena Corporation plc Insider Trades
Insider Sales PRTA / Prothena Corporation plc - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ALKS / Alkermes plc. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2014-02-03 PRTA PERRIGO Co plc 3,182,253 24.9600 3,182,253 24.9600 79,429,035 164 17.2600 -24,503,347 -30.85

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

PRTA / Prothena Corporation plc Insider Trades
Insider Purchases SNGX / Soligenix, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ALKS / Alkermes plc. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SNGX / Soligenix, Inc. Insider Trades
Insider Sales SNGX / Soligenix, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ALKS / Alkermes plc. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2004-02-13 DOR ELAN CORP PLC 17,000 1.0800 17,000 1.0800 18,360 731
2004-02-13 DOR ELAN CORP PLC 33,200 1.0700 33,200 1.0700 35,524
2004-02-13 DOR ELAN CORP PLC 12,600 1.0600 12,600 1.0600 13,356
2004-02-13 DOR ELAN CORP PLC 51,300 1.0400 51,300 1.0400 53,352
2004-02-13 DOR ELAN CORP PLC 68,200 1.0300 68,200 1.0300 70,246
2004-02-13 DOR ELAN CORP PLC 248,700 1.0200 248,700 1.0200 253,674
2004-02-13 DOR ELAN CORP PLC 875,300 1.0100 875,300 1.0100 884,053
2004-02-12 DOR ELAN CORP PLC 11,000 1.0600 11,000 1.0600 11,660
2004-02-12 DOR ELAN CORP PLC 69,200 1.0500 69,200 1.0500 72,660
2004-02-12 DOR ELAN CORP PLC 5,600 1.0200 5,600 1.0200 5,712
2004-02-12 DOR ELAN CORP PLC 180,700 1.0100 180,700 1.0100 182,507
2004-02-11 DOR ELAN CORP PLC 52,879 1.1100 52,879 1.1100 58,696
2004-02-11 DOR ELAN CORP PLC 81,000 1.1000 81,000 1.1000 89,100
2004-02-11 DOR ELAN CORP PLC 10,400 1.0900 10,400 1.0900 11,336
2004-02-11 DOR ELAN CORP PLC 16,600 1.0800 16,600 1.0800 17,928
2004-02-11 DOR ELAN CORP PLC 4,800 1.0700 4,800 1.0700 5,136
2004-02-11 DOR ELAN CORP PLC 44,900 1.0600 44,900 1.0600 47,594
2004-02-11 DOR ELAN CORP PLC 106,900 1.0500 106,900 1.0500 112,245

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SNGX / Soligenix, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Corp Plc Elan as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2014-02-04 2014-02-03 4 PRTA Prothena Corp plc
Ordinary Shares
S - Sale -3,182,253 0 -100.00 24.96 -79,429,035
2013-08-02 3 MBARD Lipocine Inc.
Common Stock
800,394
2012-12-28 3 PRTA Prothena Corp plc
Ordinary Shares
3,182,253
2012-03-14 2012-03-13 4 ALKS Alkermes plc.
Ordinary Shares
S - Sale -24,150,000 7,750,000 -75.71 15.80 -381,570,000 122,450,000
2011-09-26 3 ALKS Alkermes plc.
Common Stock
31,900,000
2005-01-10 2005-01-06 4 TGEN TARGETED GENETICS CORP /WA/
Common Stock
S - Sale -43,600 11,626,282 -0.37 1.75 -76,300 20,345,994
2005-01-06 2005-01-05 4 TGEN TARGETED GENETICS CORP /WA/
Common Stock
S - Sale -225,335 11,669,882 -1.89 1.75 -394,336 20,422,294
2005-01-06 2005-01-05 4 TGEN TARGETED GENETICS CORP /WA/
Common Stock
S - Sale -14,465 11,895,217 -0.12 1.76 -25,458 20,935,582
2005-01-06 2005-01-05 4 TGEN TARGETED GENETICS CORP /WA/
Common Stock
S - Sale -10,200 11,909,682 -0.09 1.80 -18,360 21,437,428
2005-01-06 2005-01-04 4 TGEN TARGETED GENETICS CORP /WA/
Common Stock
S - Sale -77,919 11,919,882 -0.65 1.70 -132,462 20,263,799
2005-01-06 2005-01-04 4 TGEN TARGETED GENETICS CORP /WA/
Common Stock
S - Sale -1,750 11,997,801 -0.01 1.71 -2,992 20,516,240
2005-01-06 2005-01-04 4 TGEN TARGETED GENETICS CORP /WA/
Common Stock
S - Sale -7,591 11,999,551 -0.06 1.72 -13,057 20,639,228
2005-01-06 2005-01-04 4 TGEN TARGETED GENETICS CORP /WA/
Common Stock
S - Sale -24,500 12,007,142 -0.20 1.75 -42,875 21,012,498
2005-01-06 2005-01-04 4 TGEN TARGETED GENETICS CORP /WA/
Common Stock
S - Sale -3,800 12,031,642 -0.03 1.76 -6,688 21,175,690
2005-01-06 2005-01-04 4 TGEN TARGETED GENETICS CORP /WA/
Common Stock
S - Sale -20,690 12,035,442 -0.17 1.77 -36,621 21,302,732
2005-01-06 2005-01-04 4 TGEN TARGETED GENETICS CORP /WA/
Common Stock
S - Sale -6,400 12,056,132 -0.05 1.78 -11,392 21,459,915
2005-01-06 2005-01-04 4 TGEN TARGETED GENETICS CORP /WA/
Common Stock
S - Sale -1,400 12,062,532 -0.01 1.80 -2,520 21,712,558
2005-01-06 2005-01-04 4 TGEN TARGETED GENETICS CORP /WA/
Common Stock
S - Sale -950 12,063,932 -0.01 1.81 -1,720 21,835,717
2004-04-02 2004-03-31 4 TGEN TARGETED GENETICS CORP /WA/
Series B Convertible Exchangeable Preferred Stock
C - Conversion -12,015 0 -100.00
2004-04-02 2004-03-31 4 TGEN TARGETED GENETICS CORP /WA/
Common Stock
C - Conversion 4,330,000 12,064,882 55.98 3.32 14,375,600 40,055,408
2004-02-18 2004-02-13 4 DOR DOR BIOPHARMA INC
Common Stock
S - Sale -875,300 162,600 -84.33 1.01 -884,053 164,226
2004-02-18 2004-02-13 4 DOR DOR BIOPHARMA INC
Common Stock
S - Sale -248,700 1,037,900 -19.33 1.02 -253,674 1,058,658
2004-02-18 2004-02-13 4 DOR DOR BIOPHARMA INC
Common Stock
S - Sale -68,200 1,286,600 -5.03 1.03 -70,246 1,325,198
2004-02-18 2004-02-13 4 DOR DOR BIOPHARMA INC
Common Stock
S - Sale -51,300 1,354,800 -3.65 1.04 -53,352 1,408,992
2004-02-18 2004-02-13 4 DOR DOR BIOPHARMA INC
Common Stock
S - Sale -12,600 1,406,100 -0.89 1.06 -13,356 1,490,466
2004-02-18 2004-02-13 4 DOR DOR BIOPHARMA INC
Common Stock
S - Sale -33,200 1,418,700 -2.29 1.07 -35,524 1,518,009
2004-02-18 2004-02-13 4 DOR DOR BIOPHARMA INC
Common Stock
S - Sale -17,000 1,451,900 -1.16 1.08 -18,360 1,568,052
2004-02-13 2004-02-12 4 DOR DOR BIOPHARMA INC
Common Stock
S - Sale -180,700 1,468,900 -10.95 1.01 -182,507 1,483,589
2004-02-13 2004-02-12 4 DOR DOR BIOPHARMA INC
Common Stock
S - Sale -5,600 1,649,600 -0.34 1.02 -5,712 1,682,592
2004-02-13 2004-02-12 4 DOR DOR BIOPHARMA INC
Common Stock
S - Sale -69,200 1,655,200 -4.01 1.05 -72,660 1,737,960
2004-02-13 2004-02-12 4 DOR DOR BIOPHARMA INC
Common Stock
S - Sale -11,000 1,724,400 -0.63 1.06 -11,660 1,827,864
2004-02-13 2004-02-11 4 DOR DOR BIOPHARMA INC
Common Stock
S - Sale -106,900 1,735,400 -5.80 1.05 -112,245 1,822,170
2004-02-13 2004-02-11 4 DOR DOR BIOPHARMA INC
Common Stock
S - Sale -44,900 1,842,300 -2.38 1.06 -47,594 1,952,838
2004-02-13 2004-02-11 4 DOR DOR BIOPHARMA INC
Common Stock
S - Sale -4,800 1,887,200 -0.25 1.07 -5,136 2,019,304
2004-02-13 2004-02-11 4 DOR DOR BIOPHARMA INC
Common Stock
S - Sale -16,600 1,892,000 -0.87 1.08 -17,928 2,043,360
2004-02-13 2004-02-11 4 DOR DOR BIOPHARMA INC
Common Stock
S - Sale -10,400 1,908,600 -0.54 1.09 -11,336 2,080,374
2004-02-13 2004-02-11 4 DOR DOR BIOPHARMA INC
Common Stock
S - Sale -81,000 1,919,000 -4.05 1.10 -89,100 2,110,900
2004-02-13 2004-02-11 4 DOR DOR BIOPHARMA INC
Common Stock
S - Sale -52,879 2,000,000 -2.58 1.11 -58,696 2,220,000
2004-02-06 2004-02-04 4 DOR DOR BIOPHARMA INC
Series B Convertible Preferred Stock
J - Other 126,567 126,567
2004-02-06 2002-12-12 4 DOR DOR BIOPHARMA INC
Common Stock
J - Other 500,000 2,052,879 32.20
2004-02-06 2002-10-21 4 DOR DOR BIOPHARMA INC
Series C Convertible Preferred Stock
C - Conversion -110,323 0 -100.00
2004-02-06 2002-10-21 4 DOR DOR BIOPHARMA INC
Common Stock
C - Conversion 1,245,187 1,552,879 404.69 8.86 11,032,357 13,758,508
2003-11-05 2003-09-02 4 TGEN TARGETED GENETICS CORP /WA/
Series B Convertible Exchangeable Preferred Stock
J - Other 0
2003-11-05 2003-09-02 4 TGEN TARGETED GENETICS CORP /WA/
Convertible Promissory Note
J - Other 302,934.00
2003-11-05 2003-09-02 4 TGEN TARGETED GENETICS CORP /WA/
Convertible Promissory Note
J - Other 63,420.00
2003-11-05 2003-09-02 4 TGEN TARGETED GENETICS CORP /WA/
Convertible Promissory Note
J - Other 190,800.00
2003-11-05 2003-09-02 4 TGEN TARGETED GENETICS CORP /WA/
Convertible Promissory Note
J - Other 127,200.00
2003-11-05 2003-09-02 4 TGEN TARGETED GENETICS CORP /WA/
Convertible Promissory Note
J - Other 134,832.00
2003-11-05 2003-09-02 4 TGEN TARGETED GENETICS CORP /WA/
Convertible Promissory Note
J - Other 57,000.00
2003-11-05 2003-09-02 4 TGEN TARGETED GENETICS CORP /WA/
Convertible Promissory Note
J - Other 180,000.00
2003-11-05 2003-09-02 4 TGEN TARGETED GENETICS CORP /WA/
Convertible Promissory Note
J - Other 120,000.00
2003-11-05 2003-09-02 4 TGEN TARGETED GENETICS CORP /WA/
Convertible Promissory Note
J - Other 127,200.00
2003-11-05 2003-09-02 4 TGEN TARGETED GENETICS CORP /WA/
Convertible Promissory Note
J - Other 950,000.00
2003-11-05 2003-09-02 4 TGEN TARGETED GENETICS CORP /WA/
Convertible Promissory Note
J - Other 3,000,000.00
2003-11-05 2003-09-02 4 TGEN TARGETED GENETICS CORP /WA/
Convertible Promissory Note
J - Other 2,000,000.00
2003-11-05 2003-09-02 4 TGEN TARGETED GENETICS CORP /WA/
Convertible Promissory Note
J - Other 120,000.00
2003-11-05 2003-09-02 4 TGEN TARGETED GENETICS CORP /WA/
Convertible Promissory Note
J - Other 2,000,000.00
2003-11-05 2003-09-02 4 TGEN TARGETED GENETICS CORP /WA/
Convertible Promissory Note
J - Other 302,934.00
2003-11-05 2003-09-02 4 TGEN TARGETED GENETICS CORP /WA/
Common Stock
J - Other 277,775 7,734,882 3.72 0.49 136,110 3,790,092
2003-11-05 2003-09-02 4 TGEN TARGETED GENETICS CORP /WA/
Common Stock
J - Other 221,757 7,457,106 3.06 0.57 126,401 4,250,550
2003-11-05 2003-09-02 4 TGEN TARGETED GENETICS CORP /WA/
Common Stock
J - Other 87,922 7,235,349 1.23 0.65 57,149 4,702,977
2003-11-05 2003-09-02 4 TGEN TARGETED GENETICS CORP /WA/
Common Stock
J - Other 217,549 7,147,427 3.14 0.83 180,566 5,932,364
2003-11-05 2003-09-02 4 TGEN TARGETED GENETICS CORP /WA/
Common Stock
J - Other 124,630 6,929,878 1.83 0.96 119,645 6,652,683
2003-11-05 2003-09-02 4 TGEN TARGETED GENETICS CORP /WA/
Common Stock
J - Other 107,044 6,805,248 1.60 1.19 127,382 8,098,245
2003-11-05 2003-09-02 4 TGEN TARGETED GENETICS CORP /WA/
Common Stock
J - Other 101,439 6,698,204 1.54 1.88 190,705 12,592,624
2003-11-05 2003-09-02 4 TGEN TARGETED GENETICS CORP /WA/
Common Stock
J - Other 487,248 6,596,765 7.98 1.95 950,134 12,863,692
2003-11-05 2003-09-02 4 TGEN TARGETED GENETICS CORP /WA/
Common Stock
J - Other 3,577,879 6,109,517 141.33 2.09 7,477,767 12,768,891
2003-11-05 2003-08-09 4 TGEN TARGETED GENETICS CORP /WA/
Convertible Promissory Note
J - Other 63,420.00
2003-11-05 2003-06-28 4 TGEN TARGETED GENETICS CORP /WA/
Convertible Promissory Note
J - Other 190,800.00
2003-11-05 2003-04-25 4 TGEN TARGETED GENETICS CORP /WA/
Convertible Promissory Note
J - Other 127,200.00
2003-11-05 2003-03-26 4 TGEN TARGETED GENETICS CORP /WA/
Convertible Promissory Note
J - Other 134,832.00
2003-11-05 2003-02-09 4 TGEN TARGETED GENETICS CORP /WA/
Convertible Promissory Note
J - Other 57,000.00
2003-11-05 2002-12-28 4 TGEN TARGETED GENETICS CORP /WA/
Convertible Promissory Note
J - Other 180,000.00
2003-11-05 2002-10-25 4 TGEN TARGETED GENETICS CORP /WA/
Convertible Promissory Note
J - Other 120,000.00
2003-11-05 2002-09-26 4 TGEN TARGETED GENETICS CORP /WA/
Convertible Promissory Note
J - Other 127,200.00
2003-11-05 2002-08-09 4 TGEN TARGETED GENETICS CORP /WA/
Convertible Promissory Note
P - Purchase 950,000.00
2003-11-05 2002-06-28 4 TGEN TARGETED GENETICS CORP /WA/
Convertible Promissory Note
P - Purchase 3,000,000.00
2003-11-05 2002-04-25 4 TGEN TARGETED GENETICS CORP /WA/
Convertible Promissory Note
P - Purchase 2,000,000.00
2003-11-05 2002-03-26 4 TGEN TARGETED GENETICS CORP /WA/
Convertible Promissory Note
J - Other 120,000.00
2003-11-05 2001-09-26 4 TGEN TARGETED GENETICS CORP /WA/
Convertible Promissory Note
P - Purchase 2,000,000.00
2003-11-05 2000-08-09 4 TGEN TARGETED GENETICS CORP /WA/
Common Stock
P - Purchase 382,739 2,531,638 17.81 13.06 5,000,102 33,073,319
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)